These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 7503662)
1. The diagnostic value of thrombomodulin immunolocalization in serous effusions. Ascoli V; Scalzo CC; Taccogna S; Nardi F Arch Pathol Lab Med; 1995 Dec; 119(12):1136-40. PubMed ID: 7503662 [TBL] [Abstract][Full Text] [Related]
2. Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma. Comin CE; Novelli L; Boddi V; Paglierani M; Dini S Hum Pathol; 2001 May; 32(5):529-36. PubMed ID: 11381372 [TBL] [Abstract][Full Text] [Related]
3. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions. Friedman MT; Gentile P; Tarectecan A; Fuchs A Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609 [TBL] [Abstract][Full Text] [Related]
4. Distinction between carcinoma cells and mesothelial cells in serous effusions. Usefulness of immunohistochemistry. Tickman RJ; Cohen C; Varma VA; Fekete PS; DeRose PB Acta Cytol; 1990; 34(4):491-6. PubMed ID: 2197840 [TBL] [Abstract][Full Text] [Related]
5. Immunocytochemistry in the differential diagnosis of serous effusions: a comparative evaluation of eight monoclonal antibodies in Papanicolaou stained smears. Lozano MD; Panizo A; Toledo GR; Sola JJ; Pardo-Mindán J Cancer; 2001 Feb; 93(1):68-72. PubMed ID: 11241268 [TBL] [Abstract][Full Text] [Related]
6. Differentiation of mesothelioma from adenocarcinoma in serous effusions: the role of hyaluronic acid and CD44 localization. Afify AM; Stern R; Michael CW Diagn Cytopathol; 2005 Mar; 32(3):145-50. PubMed ID: 15690337 [TBL] [Abstract][Full Text] [Related]
7. The value of calretinin and cytokeratin 5/6 as markers for mesothelioma in cell block preparations of serous effusions. Shield PW; Koivurinne K Cytopathology; 2008 Aug; 19(4):218-23. PubMed ID: 17916095 [TBL] [Abstract][Full Text] [Related]
8. Immunocytochemistry of malignant mesothelioma: OV632 as a marker of malignant mesothelioma. Delahaye M; Hoogsteden HC; Van der Kwast TH J Pathol; 1991 Oct; 165(2):137-43. PubMed ID: 1744800 [TBL] [Abstract][Full Text] [Related]
9. D2-40 is not a specific marker for cells of mesothelial origin in serous effusions. Bassarova AV; Nesland JM; Davidson B Am J Surg Pathol; 2006 Jul; 30(7):878-82. PubMed ID: 16819331 [TBL] [Abstract][Full Text] [Related]
10. Carbohydrate antigen expression in primary tumors, metastatic lesions, and serous effusions from patients diagnosed with epithelial ovarian carcinoma: evidence of up-regulated Tn and Sialyl Tn antigen expression in effusions. Davidson B; Berner A; Nesland JM; Risberg B; Kristensen GB; Tropé CG; Bryne M Hum Pathol; 2000 Sep; 31(9):1081-7. PubMed ID: 11014575 [TBL] [Abstract][Full Text] [Related]
12. Heparanase expression: a potential ancillary diagnostic tool for distinguishing between malignant cells and reactive mesothelium in body cavity effusions. Doviner V; Maly B; Reinhartz T; Vlodavsky I; Sherman Y Cytopathology; 2007 Feb; 18(1):13-9. PubMed ID: 17250598 [TBL] [Abstract][Full Text] [Related]
13. Diagnostic value of p53 protein in the study of serous effusions. Zoppi JA; Pellicer EM; Sundblad AS Acta Cytol; 1995; 39(4):721-4. PubMed ID: 7631546 [TBL] [Abstract][Full Text] [Related]
14. Utility of CD138 (syndecan-1) in distinguishing carcinomas from mesotheliomas. Saqi A; Yun SS; Yu GH; Alexis D; Taub RN; Powell CA; Borczuk AC Diagn Cytopathol; 2005 Aug; 33(2):65-70. PubMed ID: 16007640 [TBL] [Abstract][Full Text] [Related]
15. Diagnostic significance of carcinoembryonic antigen in the differential diagnosis of malignant mesothelioma. Mezger J; Lamerz R; Permanetter W J Thorac Cardiovasc Surg; 1990 Dec; 100(6):860-6. PubMed ID: 2147220 [TBL] [Abstract][Full Text] [Related]
16. Monoclonal antibody MOC-31 reactivity as a marker for adenocarcinoma in cytologic preparations. Hecht JL; Pinkus JL; Pinkus GS Cancer; 2006 Feb; 108(1):56-9. PubMed ID: 16329115 [TBL] [Abstract][Full Text] [Related]
17. A new epithelial membrane antigen (Calam 27) as a marker of carcinoma in serous effusions. Gioanni J; Caldani C; Zanghellini E; Mazeau C; Duplay H; Ferrua B; Schneider M Acta Cytol; 1991; 35(3):315-9. PubMed ID: 2042433 [TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical differentiation of malignant mesothelioma, mesothelial hyperplasia and metastatic adenocarcinoma in serous effusions, utilizing staining for carcinoembryonic antigen, keratin and vimentin. Duggan MA; Masters CB; Alexander F Acta Cytol; 1987; 31(6):807-14. PubMed ID: 2447718 [TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma. Kushitani K; Takeshima Y; Amatya VJ; Furonaka O; Sakatani A; Inai K Pathol Int; 2007 Apr; 57(4):190-9. PubMed ID: 17316414 [TBL] [Abstract][Full Text] [Related]
20. Value of the mesothelium-associated antibodies thrombomodulin, cytokeratin 5/6, calretinin, and CD44H in distinguishing epithelioid pleural mesothelioma from adenocarcinoma metastatic to the pleura. Cury PM; Butcher DN; Fisher C; Corrin B; Nicholson AG Mod Pathol; 2000 Feb; 13(2):107-12. PubMed ID: 10697265 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]